TMPRSS2-ERG Gene Fusion Causing ERG Overexpression Precedes Chromosome Copy Number Changes in Prostate Carcinomas, Paired HGPIN Lesions  by Cerveira, Nuno et al.
TMPRSS2–ERG Gene Fusion Causing ERG Overexpression
Precedes Chromosome Copy Number Changes in Prostate
Carcinomas and Paired HGPIN Lesions1
Nuno Cerveira*, Franclim R. Ribeiro*, Ana Peixoto*, Vera Costa*, Rui Henrique y,z,
Carmen Jero´nimo*,z,§ and Manuel R. Teixeira*,z
*Department of Genetics, Portuguese Oncology Institute, Porto, Portugal; yDepartment of Pathology,
Portuguese Oncology Institute, Porto, Portugal; zDepartment of Pathology and Molecular Immunology, Institute
of Biomedical Sciences, University of Porto, Porto, Portugal; §Fernando Pessoa University School
of Health Sciences, Porto, Portugal
Abstract
TMPRSS2–ETS gene fusions have been found recur-
rently in prostate carcinomas, but not in the presumed
precursor lesion, high-grade prostatic intraepithelial
neoplasia (HGPIN). However, HGPIN lesions may
share chromosomal changes with prostate cancer.
To determine the relative order of genetic events in
prostate carcinogenesis, we have analyzed 34 prostate
carcinomas, 19 paired HGPIN lesions, 14 benign pros-
tate hyperplasias, and 11 morphologically normal pro-
static tissues for TMPRSS2–ERG and TMPRSS2–ETV1
rearrangements and genomic imbalances. TMPRSS2
exon 1 was fused in-frame with ERG exon 4 in 17 of
34 (50%) prostate carcinomas and in 4 of 19 (21%)
HGPIN lesions, but in none of controls. The findings
were further validated by sequencing analysis and by
the real-time polymerase chain reaction quantification
of TMPRSS2–ERG fusion transcript and the ERG exons
5/6:exons 1/2 expression ratio. Chromosome copy
number changesweredetectedby comparativegenomic
hybridization in 42% of clinically confined carcinomas
and in none of the 16 HGPIN lesions analyzed. We dem-
onstrate for the first time that the TMPRSS2–ERG fusion
gene can be detected in a proportion of HGPIN lesions
and that this molecular rearrangement is an early event
that may precede chromosome-level alterations in
prostate carcinogenesis.
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Introduction
A central aim in cancer research is to identify genes that play
a causal role in cancer development. Many such genes have
been identified through analyses of recurrent chromosomal
rearrangements that are characteristic of leukemias, lym-
phomas, and sarcomas, typically resulting in the formation of
oncogenic fusion genes [1]. This type of specific genetic
change has only rarely been detected in common solid cancers
[2], although that can be related to the smaller number of cases
analyzed [3,4]. Recently, taking advantage of a bioinformatic
approach termed Cancer Outlier Profile Analysis, the fusion
genes TMPRSS2–ERG and TMPRSS2–ETV1 have been
detected in a high proportion of prostate carcinomas selected
for demonstrating an overexpression of the erythroblast trans-
formation specific (ETS) transcription factor ERG or ETV1 [5].
Later, a rare third fusion gene, involving the TMPRSS2 locus
and another ETS family gene ETV4, was identified [6].
The fusion partner common to the three rearrangements is
TMPRSS2, an androgen-regulated member of the type II
transmembrane serine protease family that maps to 21q22.3.
TMPRSS2 protein is preferentially expressed in normal pros-
tate tissues and is overexpressed in the neoplastic prostatic
epithelium [7–10]. Its expression seems to be regulated by
androgen-responsive elements (AREs) in a promoter [10,11],
and it has been shown that androgen stimulation can induce
the overexpression of ERG in a TMPRSS2–ERG–positive cell
line [5]. These results suggest that deregulation of ETS tran-
scription factor protein activity through AREs mapped 5V of
TMPRSS2 may underlie prostate cancer development, affect-
ing biologic processes such as cell proliferation, differentiation,
development, transformation, and apoptosis [5,12].
Although TMPRSS2–ETS gene fusions seem to be re-
current in prostate carcinomas, this genetic abnormality has
not been reported in the presumed precursor lesion, high-
grade prostatic intraepithelial neoplasia (HGPIN) [5]. How-
ever, fluorescent in situ hybridization (FISH) and comparative
Abbreviations: HGPIN, high-grade prostatic intraepithelial neoplasia; PCa, prostate adeno-
carcinomas; ETS, erythroblast transformation specific; CGH, comparative genomic hybrid-
ization; RT-PCR, reverse transcriptase– polymerase chain reaction
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genomic hybridization (CGH) data have shown that HGPIN
lesions may share genetic features with prostate cancer
(e.g., 8p deletion) [13,14]. Therefore, the time of occur-
rence and the relative order of events in ETS gene fusions
and chromosome imbalances are not known in prostate
carcinogenesis. To address this issue, we have analyzed
34 samples of clinically localized prostate adenocarcinomas
(PCa) and 19 paired HGPIN lesions for chromosome copy




Primary tumors from 34 patients with clinically localized
PCa [stage II (T1cN0M0 or T2N0M0), according to the TNM
staging system] who were consecutively diagnosed and
primarily treated with radical prostatectomy at the Portu-
guese Oncology Institute (Porto, Portugal) were prospec-
tively collected. In 19 radical prostatectomy specimens with
PCa, HGPIN lesions were identified and collected for fur-
ther analysis. For control purposes, non-neoplastic prostate
tissue samples were obtained from 14 randomly selected
patients with benign prostate hyperplasia (BPH) who under-
went transurethral resection of the prostate and from the
peripheral zone of 11 prostates that did not harbor prostate
cancer, which were collected from cystoprostatectomy (NPT)
specimens of bladder cancer patients.
Sample Collection, RNA Extraction, and cDNA Synthesis
All tissue specimens were frozen immediately after sur-
gery and stored at 80jC for further analysis. Five-micron–
thick sections were cut and stained for the identification of
areas of PCa (i.e., index or dominant tumor), HGPIN, BPH,
and morphologically normal tissues. Then, the tissue block
was trimmed to maximize the yield of target cells (> 70% of
target cells). Subsequently, an average of fifty 12-mm–thick
sections were cut, and every fifth section was stained to
ensure a uniform percentage of target cells and to exclude
contamination from neoplastic cells in normal and BPH tissue
samples. Total cellular RNA was extracted from 250 mg of
(normal and tumor) tissues using the FastRNA Kit Green
(Qbiogene, Carlsbad, CA) for 90 seconds, with a speed rating
of 6.0 in a FastPrep FP120 Instrument (Qbiogene). For cDNA
synthesis, 1 to 5 mg of RNA was subjected to reverse
transcription with random hexamers using the Superscript
III First-Strand Synthesis System for reverse transcriptase–
polymerase chain reaction (RT-PCR) (Invitrogen, Carlsbad,
CA), according to the manufacturer’s instructions. Final
cDNA was diluted with 30 ml of H2O.
RT-PCR Analysis
RT-PCR for the detection of TMPRSS2–ERG and
TMPRSS2–ETV1 chimeric transcripts was previously de-
scribed [5]. In brief, PCR was performed in a 50-ml reaction
containing 2 ml of synthesized cDNA, 5 ml of 10 GeneAmp
PCR Buffer II (100 mM Tris–HCl, pH 8.3, 500 mM KCl)
(Applied Biosystems, Foster City, CA), 5 ml of 25 mM MgCl2,
0,4 ml of dNTP mix (25 mM of each dNTP) (Applied Biosys-
tems), 0.4 mM of each primer (Metabion, Martinsried,
Deutschland), and 1 U of AmpliTaq Gold DNA Polymerase
(Applied Biosystems). Reaction tubes were kept on ice at all
times to prevent nonspecific amplification. Reaction tubes
were incubated for 10 minutes at 95jC, followed by 35 cycles
of 1 minute at 95jC, 1 minute at 63jC, and 1 minute at
72jC, followed by a final elongation of 10 minutes at 72jC on
a GeneAmp PCR System 9700 (Applied Biosystems). Am-
plified products were analyzed on a 2% agarose gel
(SeaKem LE Agarose, Rockland, MA), and the results were
visualized with an image analyzer ImageMaster VDS (Amer-
sham Biosciences, Little Chalfont, UK).
Sequence Analysis
Sequence analysis was directly performed on amplified
RT-PCR products with the use of BigDye Terminator Cycle
Sequencing Chemistry (Applied Biosystems) on an auto-
mated sequencer ABI Prism 310 Genetic Analyzer (Applied
Biosystems), according to the manufacturer’s instructions.
Real-Time PCR Analysis
Primers and probes for TMPRSS2–ERG, TMPRSS2,
ERG, and ETV1 were designed with Primer Express 2.0
(Applied Biosystems) and purchased from Metabion
(Table 1). Primers and probes for the b-glucuronidase (GUSB)
gene, used as endogenous control, were purchased as a
predeveloped assay reagent from Applied Biosystems. To
determine the relative expression levels of the target gene
in each sample, the relative amount of the target gene was
calibrated to the relative amount of the internal reference
gene and was expressed in terms of target/reference ratios
that were then multiplied by 100 for easier tabulation (target
gene/GUSB  100). PCR was performed in a 25-ml reaction
containing 5 ml of synthesized cDNA, 12.5 ml of TaqMan
universal PCR master mix, 0.3 mM of each primer, and
0.2 mM of each probe. PCR was performed in separate wells
for each primer/probe set, and each sample was run in
triplicate. PCR parameters were as follows: 50jC for 2 min-
utes, 95jC for 10 minutes, followed by 50 cycles at 95jC for
15 seconds and 60jC for 1 minute. Each plate included
multiple nontemplate controls and serial dilutions of a posi-
tive control for constructing the standard curve.
CGH Analysis
CGH analysis followed the procedure of Kallioniemi et al.
[15], with modifications, as previously described [16]. Briefly,
test and reference DNA were extracted using standard
methods and labeled in nick translation reactions using
Spectrum Green and Spectrum Red conjugated nucleotides
(Vysis, Downers Grove, IL), after which probe lengths be-
tween 300 and 2000 bp were obtained. Labeled sample and
reference DNA (1 mg each) were mixed with 30 mg of un-
labeled Cot1 DNA (Life Technologies, Rockville, MD),
ethanol-precipitated, dried, and dissolved in hybridization
buffer (Vysis). Probe mixture was denatured and hybridized
to commercially available normal metaphase slides (Vysis)
TMPRSS2–ERG Fusion in Prostate Cancer and HGPIN Cerveira et al. 827
Neoplasia . Vol. 8, No. 10, 2006
for 2 to 3 days at 37jC in a moist chamber. After washing off
excess probe, samples were counterstained with DAPI in an
antifade solution (Vector Laboratories, Burlingame, CA).
Image analysis was performed with CytoVision System
version 3.0 (Applied Imaging, Santa Clara, CA). Data from
10 cells were combined to generate average ratio profiles
with 99% confidence intervals (CIs) for each sample. A stan-
dard reference interval, generated with data from 10 normal
versus normal hybridizations (totaling 110 cells), was auto-
matically scaled onto each sample, and aberrations were
scored whenever the case profile and the standard reference
profile at 99%CI did not overlap [17]. The description of CGH
copy number changes followed the guidelines suggested
in ISCN [18].
Results
Frequency of TMPRSS2–ERG and TMPRSS2–ETV1
Fusion Transcripts
To estimate the frequency of TMPRSS2–ERG and
TMPRSS2–ETV1 chimeric transcripts, we have screened a
consecutive series of 34 patients with clinically localized PCa
and 19 paired HGPIN. Type A TMPRSS2–ERG transcript
could be detected in 17 of 34 (50%) prostate carcinomas
and in 4 of 19 (21%) HGPIN lesions, but in none of controls
(Figure 1A). When we consider all patient samples regard-
less of lesion type (i.e., PCa or HGPIN), this frequency rises
to 56% (19 of 34) because, in two negative PCa cases, the
corresponding HGPIN was positive (Table 2). No type B
TMPRSS2–ERG or TMPRSS2–ETV1 fusion transcript
was detected in any of the samples analyzed. The sequenc-
ing of amplification products, followed by BLAST search,
confirmed that TMPRSS2 exon 1 was fused in-frame with
ERG2 exon 4 (Figure 1B).
TMPRSS2–ERG Fusion Transcript Quantification
To validate the findings regarding TMPRSS2–ERG, we
designed a specific primer pair and probe for the type A
TMPRSS2–ERG transcript. All RT-PCR–positive cases
were quantified and, as additional negative controls, some
TMPRSS2–ERG–negative cases were also analyzed. Only
the previously identified RT-PCR–positive cases (PCa
and HGPIN) showed amplification by real-time PCR, with
TMPRSS2–ERG normalized values ranging from 1.55 to
530.63 in PCa and from 1.02 to 17.19 in HGPIN (Table 2).
All TMPRSS2–ERG–negative cases analyzed showed no
amplification by real-time PCR.
Relationship between TMPRSS2–ERG Fusion and ERG
Overexpression
To evaluate the relationship between TMPRSS2–ERG
detection and ERG expression in our series, we designed
specific primer pairs and probes for ERG exons 1 and 2 and
for ERG exons 5 and 6. Quantitative RT-PCR revealed that
the ERG exons 5/6:exons 1/2 ratio was higher than 2.5 in all
TMPRSS2–ERG–positive (but in none of negative) prostate
carcinomas (Table 2). The relationship between the presence
of TMPRSS2–ERG fusion and ERG overexpression was
less constant in HGPIN lesions because only one of four
positive cases for the TMPRSS2–ERG fusion showed an
ERG exons 5/6:exons 1/2 ratio above 2.5. Regarding the
control group, none of 11 NPT samples showed an ERG
exons 5/6:exons 1/2 ratio above 2.5, but in one case of BPH
(BPH 84), the ERG exons 5/6:exons 1/2 ratio was clearly
above 2.5 (Table 2).
CGH Findings
Sixteen of 19 HGPIN lesions yielded enough DNA and
were analyzed in the present study. Genomic data on 34 PCa
and 14 BPH samples were previously published [14]. Chro-
mosome copy number changes were detected in 42% of
PCa samples (Table 2), with the most frequent alteration
corresponding to 8p loss (10 of 13 samples with copy number
changes). Of the 17 TMPRSS2–ERG–positive carcinomas,
eight were shown to harbor genomic imbalances. All HGPIN
lesions presented a balanced chromosome constitution. No
statistically significant correlation could be established be-
tween specific genetic alterations and the presence of the
TMPRSS2–ERG fusion transcript, but all three PCa with
8q gain did not harbor the fusion gene.
Discussion
We have confirmed that a high proportion of prostate carci-
nomas presents the TMPRSS2–ERG rearrangement. In our
consecutive series of clinically localized PCa, this genetic
anomaly was detected in 50% of cases, making it the most
Table 1. Oligonucleotide Primers and Probes (5VFAM and 3VTAMRA) Used in This Study.
Gene Exon Position Primer/Probe* Sequence 5V–3V
ERG 1 3–22 ERG1-S CCCGAGGGACATGAGAGAAG
ERG 2 50–69 ERG2-AS TTTCCTCGGGTCTCCAAAGA
ERG 1–2 26–48 ERG12-PR AGCGGCGCTCAGGTTATTCCAGG
ERG 5 564–583 ERG5-S CACGAACGAGCGCAGAGTTA
ERG 6 611–630 ERG6-AS CTGCCGCACATGGTCTGTAC
ERG 5–6 585–609 ERG56-PR CGTGCCAGCAGATCCTACGCTATGG
TMPRSS2 1 4–17 TMPRSS2/ERG-S TAGGCGCGAGCTAAGCAGGAG
ERG 4 252–276 TMPRSS2/ERG-AS GTAGGCACACTCAAACAACGACTGG
TMPRSS2–ERG – – TMPRSS2/ERG-PR AGCGCGGCAGGAAGCCTTATCAGTT
The GenBank accession numbers for TMPRSS2 and ERG are NM_005656.2 and NM_004449.3, respectively.
*S = sense; AS = antisense; PR = probe.
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frequent fusion gene in human carcinomas. This finding was
confirmed by quantitative real-time RT-PCR targeting the
fusion gene. Furthermore, theERG exons 5/6:exons 1/2 ratio
was higher than 2.5 in all TMPRSS2–ERG–positive (but
in none of negative) prostate carcinomas. Our results are in
agreement with Tomlins et al. [5] who, using FISH analysis,
reported the presence of ERG rearrangement in 55% (16 of
29) of a series of 29 prostate carcinomas selected inde-
pendently of any knowledge of ERG or ETV1 expression
[5]. However, Soller et al. [19] reported a TMPRSS2–ERG
fusion frequency of 79%. This discrepancy can be due to the
lower number of cases (n = 18) studied by Soller et al. [19]
and/or to their use of nested PCR. Indeed, when we used
nestedPCR in our samples, the frequency of theTMPRSS2–
ERG transcript rose to 62%, but, additionally, three control
samples (one HBP and two CP) also showed a clear positive
signal (data not shown). False-positive results with highly
sensitive PCR techniques for the detection of fusion tran-
scripts are relatively rare, but are a major concern in patients
with hematologic malignancies [20,21]. These can be due to
contamination from previous positive cases or to the pres-
ence of very rare normal cells with abnormal molecular
rearrangements characteristic of specific types of hemato-
logic malignancies (e.g., BCR–ABL gene fusion in chronic
myeloid leukemia and BCL2 gene rearrangement in follicu-
lar lymphoma) [20,21]. As a consequence, one should be
aware of the potential risks of using nested PCR in diagnostic
samples, despite scrupulous precautions taken to minimize
contamination. Conversely,TMPRSS2–ETV1 fusionwas not
detected in any of our cases. This is in agreement with
previous reported frequencies of 3% (1 of 32) and 0% (0
of 18) [5,18], suggesting that this molecular rearrangement,
as with TMPRSS2–ETV4 fusion [6], is not a frequent event
in prostate cancer.
To the best of our knowledge, this is the first study to report
on the presence of TMPRSS2–ERG fusion in HGPIN le-
sions (21% of cases in our series). The detection of the
TMPRSS2–ERG fusion gene in HGPIN is not unexpected
Figure 1. Detection and analysis of type A TMPRSS2–ERG fusion transcript in prostate carcinoma and HGPIN samples. (A) RT-PCR analysis with a sense primer
located in TMPRSS2 exon 1 and an antisense primer located in ERG exon 6 in PCa (PCa 55, PCa 114, PCa 134, and PCa 152 in lanes 2–5, respectively) and
HGPIN (HGPIN 60, HGPIN 83, and HGPIN 42 in lanes 7–9, respectively) samples. The expected size of the type A TMPRSS2–ERG fusion transcript is indicated.
Lanes 1, 6, and 10 = 100-bp molecular marker. (B) Partial sequence of the junction of type A TMPRSS2–ERG chimeric mRNA showing the nucleotide sequence of
the fusion transcript. The arrow shows in-frame fusion between TMPRSS2 exon 1 and ERG exon 4.
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Table 2. Qualitative RT-PCR (Column 2), Quantitative RT-PCR (Columns 3 and 4), and CGH (Column 5) Findings of a Consecutive Series of PCa, Paired HGPIN,







CGH Findings (Standard Reference Interval [SRI] 99% CI)
PCa 32 Positive, type A 19.42 4.77 Rev ish dim(8p12pter)
HGPIN 32 – 0.00 0.44 No changes
PCa 40 Positive, type A 530.63 52.45 No changes
HGPIN 40 – 0.00 1.39 No changes
PCa 42 – ND 1.25 No changes
HGPIN 42 Positive, type A 1.02 0.79 No changes
PCa 45 Positive, type A 8.01 2.87 Rev ish dim(8p12p22)
HGPIN 45 – ND 0.37 ND
PCa 46 – ND 1.97 ND
HGPIN 46 – ND 0.41 No changes
PCa 55 – ND 2.29 Rev ish enh(3q23q26,7p13p21,7q21q32,8q21q24),
dim(16q22qter)
HGPIN 55 – 0.00 4.23 No changes
PCa 56 – ND 2.08 No changes
PCa 58 – ND 2.38 Rev ish enh(8q21q24), dim(8p22)
HGPIN 58 Positive, type A 1.73 17.47 No changes
PCa 60 Positive, type A 37.56 4.69 No changes
HGPIN 60 Positive, type A 17.19 2.48 No changes
PCa 67 Positive, type A 120.91 111.61 Rev ish dim(8p21pter)
PCa 72 – ND 0.44 Rev ish enh(5p14pter,5q11q23,5q32q33)
PCa 76 – ND 1.72 Rev ish enh(8q), dim(2q23q24,8p12p23,10p11p12,10q22q25)
PCa 78 – ND 1.73 ND
HGPIN 78 – ND 1.85 No changes
PCa 81 Positive, type A 112.83 10.41 No changes
PCa 83 Positive, type A 24.79 13.84 No changes
HGPIN 83 Positive, type A 1.87 1.01 ND
PCa 84 – 0.00 1.34 No changes
HGPIN 84 – ND 1.08 No changes
PCa 87 – ND 1.35 No changes
HGPIN 87 – ND 0.76 No changes
PCa 89 Positive, type A 149.02 7.47 No changes
PCa 101 Positive, type A 19.43 6.44 Rev ish enh(18p11), dim(8p22pter,13q14q22)
PCa 114 Positive, type A 493.30 47.07 Rev ish dim(16q22qter)
PCa 115 – ND 2.17 No changes
HGPIN 115 – 0.00 2.98 No changes
PCa 131 – ND 1.45 No changes
PCa 134 – 0.00 1.18 No changes
PCa 138 Positive, type A 13.58 31.49 ND
HGPIN 138 – 0.00 0.29 No changes
PCa 139 Positive, type A 62.40 59.25 Rev ish dim(8p22pter,17p13)
PCa 140 Positive, type A 11.62 5.84 No changes
PCa 145 Positive, type A 1.55 4.70 No changes
HGPIN 145 – 0.00 1.68 No changes
PCa 147 – ND 2.24 No changes
HGPIN 147 – ND 0.57 No changes
PCa 150 – ND 0.53 No changes
HGPIN 150 – ND 1.03 No changes
PCa 151 – 0.00 0.29 No changes
PCa 152 Positive, type A 206.05 9.62 No changes
PCa 156 – ND 1.69 Rev ish dim(6q15q21,8p21p23,13q21q31)
HGPIN 156 – 0.00 0.82 ND
PCa 164 Positive, type A 57.74 6.34 Rev ish dim(8p12p22,10q22qter,13q14q21,16q23q24)
HGPIN 164 – 0.00 0.42 ND
PCa 172 Positive, type A 155.73 6.94 Rev ish dim(8p12p22,17p12pter)
NPT 1 – ND 0.84 ND
NPT 3 – 0.00 2.08 ND
NPT 5 – ND 0.44 ND
NPT 6 – ND 0.45 ND
NPT 7 – 0.00 1.96 ND
NPT 8 – ND 0.23 ND
NPT 10 – ND 0.07 ND
NPT 11 – ND 0.47 ND
NPT 12 – 0.00 0.19 ND
NPT 13 – 0.00 0.37 ND
NPT 14 – 0.00 0.10 ND
BPH 7 – ND 0.70 No changes
BPH 17 – ND 0.32 No changes
BPH 36 – ND 0.12 No changes
BPH 55 – ND 0.38 No changes
BPH 68 – ND 0.06 No changes
BPH 71 – ND 0.08 No changes
BPH 76 – ND 0.35 No changes
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because this lesion is considered to be a precursor of, at
least, some prostate carcinomas [22]. Indeed, histologic data
seem to support this hypothesis: HGPIN consists of archi-
tecturally benign prostatic acini lined by cells that seem to be
malignant (Figure 2), and prostate carcinomas may have
zones of HGPIN from which glands of carcinoma seem to
stem [22–24]. In addition, prostates with carcinoma have
more of these foci than do those without carcinoma; prostate
glands with extensive HGPIN also have more multifocal
carcinomas; and HGPIN lesions preferentially develop in
the peripheral zone of the prostate, which is the site of origin
for most adenocarcinomas [22,25]. Interestingly, in two pa-
tients (cases 42 and 58), the fusion transcript was detected in
the HGPIN lesion, but not in the PCa present in the same
gland. This observation supports the hypothesis that prostate
carcinogenesis may be a multicentric process, in which at
least two independent pathogenetic pathways may coexist in
the same prostate, leading to independent neoplasias with or
without the involvement of the ETS pathway.
As opposed to prostate carcinomaswithTMPRSS2–ERG
fusion, where a clear association between TMPRSS2–ERG
positivity and ERG overexpression was observed, this rela-
tionship was less constant in HGPIN lesions, with only one of
four positive cases for the TMPRSS2–ERG fusion showing
an ERG exons 5/6:exons 1/2 ratio above 2.5. These find-
ings are compatible with the hypothesis that HGPIN lesions
may initially be polyclonal proliferations, with the cells with
TMPRSS2–ERG fusion being diluted in a pool of cells
not harboring this alteration. Presumably, the HGPIN le-
sion may eventually be dominated by the clone with the
TMPRSS2–ERG fusion as a result of clonal expansion, as
shown by the detection of ERG overexpression in a subset
of HGPIN lesions.
Although no correlation could be established between
specific copy number changes detected by CGH and the
presence of the TMPRSS2–ERG fusion transcript or ERG
overexpression, several interesting conclusions can be
drawn from our results. When we consider the group of PCa
and HGPIN samples with TMPRSS2–ERG fusion, only eight
of PCa cases and none of HGPIN samples showed copy
number changes by CGH, indicating that the TMPRSS2–
ERG fusion is an early pathogenetic event in prostate
carcinogenesis that precedes the acquisition of chromosome
imbalances. Because none of theTMPRSS2–ERG–positive
cases showed a gain of 8q, a genomic imbalance recently
identified as an independent predictor of poor survival [16],
it is possible that the TMPRSS2–ERG gene fusion could
represent a class of clinically less aggressive prostate carci-
nomas, but this needs to be addressed in a larger series.







CGH Findings (SRI 99% CI)
BPH 79 – 0.00 2.05 No changes
BPH 84 – 0.00 24.68 No changes
BPH 89 – 0.00 0.40 No changes
BPH 91 – ND 0.32 No changes
BPH 92 – ND 0.16 No changes
BPH 96 – ND 0.28 No changes
ND, not done.
Figure 2. Representative images of four HGPIN lesions harboring the
TMPRSS2–ERG fusion gene. (A) HGPIN 42. (B) HGPIN 58. (C) HGPIN 60.
(D) HGPIN 83 (hematoxylin –eosin stain; original magnification, 25).
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In summary, we confirm that fusion of the ETS tran-
scription factor ERG with the TMPRSS2 gene is a frequent
event in prostate cancer. Furthermore, we demonstrate for
the first time that TMPRSS2–ERG fusion can already be
detected in a proportion of HGPIN lesions and that this
molecular rearrangement is an early event that may precede
chromosome-level alterations in prostate carcinogenesis.
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